Long-term renal and pancreas function with tacrolimus rescue therapy following kidney/pancreas transplantation.
Hariharan
S
S
Department of Internal Medicine, University of Cincinnati Medical Center, Ohio, USA.
Peddi
V R
VR
Munda
R
R
Demmy
A M
AM
Schroeder
T J
TJ
Alexander
J W
JW
First
M R
MR
D000328:Adult; D001160:Arterioles / Q000473:pathology; D001786:Blood Glucose / Q000378:metabolism; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000032:analysis; D006084:Graft Rejection / Q000453:epidemiology / Q000628:therapy; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000473:pathology / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D016035:Pancreas Transplantation / Q000276:immunology / Q000473:pathology / Q000502:physiology*; D011183:Postoperative Complications; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors
D001786:Blood Glucose; D003404:Creatinine; D016572:Cyclosporine; D006442:Glycated Hemoglobin; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016559:Tacrolimus